Aquestive Therapeutics Overview
- Status
-
Public
- Employees
-
135
- Stock Symbol
-
AQST
- Investments
-
3
- Share Price
-
$4.83
- (As of Monday Closing)
Aquestive Therapeutics General Information
Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Contact Information
Website
www.aquestive.comCorporate Office
- 30 Technology Drive
- Warren, NJ 07059
- United States
Corporate Office
- 30 Technology Drive
- Warren, NJ 07059
- United States
Aquestive Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.83 | $4.89 | $1.36 - $6.23 | $441M | 91.1M | 1.3M | -$0.35 |
Aquestive Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 175,980 | 154,990 | 85,291 | 168,517 |
| Revenue | 58,360 | 50,583 | 47,680 | 50,832 |
| EBITDA | (15,119) | (15,174) | (39,680) | (45,537) |
| Net Income | (25,719) | (7,870) | (54,410) | (70,539) |
| Total Assets | 117,605 | 57,418 | 57,070 | 61,993 |
| Total Debt | 35,723 | 33,319 | 57,488 | 56,421 |
Aquestive Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aquestive Therapeutics Comparisons
Industry
Financing
Details
Aquestive Therapeutics Competitors (35)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Marinus Pharmaceuticals | Formerly VC-backed | Radnor, PA | ||||
| Vanda Pharmaceuticals | Formerly VC-backed | Washington, DC | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Santhera Pharmaceuticals | Formerly VC-backed | Pratteln, Switzerland |
Aquestive Therapeutics Patents
Aquestive Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240016734-A1 | Enhanced delivery epinephrine and prodrug compositions | Pending | 14-Jun-2022 | ||
| US-20230131450-A1 | Oral and nasal compositions and methods of treatment | Pending | 25-Oct-2021 | ||
| EP-4422607-A1 | Oral and nasal compositions and methods of treatment | Pending | 25-Oct-2021 | ||
| US-20230130055-A1 | Pharmaceutical compositions with enhanced stability profiles | Pending | 22-Oct-2021 | ||
| CA-3236045-A1 | Pharmaceutical compositions with enhanced stability profiles | Pending | 22-Oct-2021 | A61K47/36 |
Aquestive Therapeutics Executive Team (14)
| Name | Title | Board Seat |
|---|---|---|
| Daniel Barber | President, Chief Executive Officer & Board Member | |
| Ernie Toth | Chief Financial Officer & Senior Vice President | |
| Cassie Jung | Chief Operating Officer, Operations | |
| Mark Schobel | Chief Innovation and Technology Officer | |
| Stephen Wargacki | Executive |
Aquestive Therapeutics Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Self | Board Member | ||
| Aquestive Therapeutics | President, Chief Executive Officer & Board Member | ||
| Self | Chairman & Board Member | ||
| Self | Board Member | ||
| Self | Board Member |
Aquestive Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aquestive Therapeutics Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Adept Polymers | 29-May-2007 | Other Materials | |||
| Stanelco (Certain Equipment and Intellectual Property) | 29-May-2007 | Other Containers and Packaging | |||
| RespondTV | 26-Jul-2000 | Later Stage VC | Social Content |
Aquestive Therapeutics ESG
Risk Overview
Risk Rating
Updated June, 13, 2021
55.73 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile
Pharmaceuticals
Industry
of 947
Rank
Percentile
Pharmaceuticals
Subindustry
of 452
Rank
Percentile
Aquestive Therapeutics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| RespondTV | 26-Jul-2000 | Completed |
|
Aquestive Therapeutics FAQs
-
Who is the CEO of Aquestive Therapeutics?
Daniel Barber is the CEO of Aquestive Therapeutics.
-
Where is Aquestive Therapeutics headquartered?
Aquestive Therapeutics is headquartered in Warren, NJ.
-
What is the size of Aquestive Therapeutics?
Aquestive Therapeutics has 135 total employees.
-
What industry is Aquestive Therapeutics in?
Aquestive Therapeutics’s primary industry is Drug Delivery.
-
Is Aquestive Therapeutics a private or public company?
Aquestive Therapeutics is a Public company.
-
What is Aquestive Therapeutics’s stock symbol?
The ticker symbol for Aquestive Therapeutics is AQST.
-
What is the current stock price of Aquestive Therapeutics?
As of 14-Oct-2024 the stock price of Aquestive Therapeutics is $4.83.
-
What is the current market cap of Aquestive Therapeutics?
The current market capitalization of Aquestive Therapeutics is $441M.
-
What is Aquestive Therapeutics’s current revenue?
The trailing twelve month revenue for Aquestive Therapeutics is $58.4M.
-
Who are Aquestive Therapeutics’s competitors?
Crinetics Pharmaceuticals, Marinus Pharmaceuticals, Vanda Pharmaceuticals, Novartis, and Santhera Pharmaceuticals are some of the 35 competitors of Aquestive Therapeutics.
-
What is Aquestive Therapeutics’s annual earnings per share (EPS)?
Aquestive Therapeutics’s EPS for 12 months was -$0.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
